ClinicalTrials.gg
RecruitingNCT06568471Updated Feb 6, 2025

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

A Phase 3 interventional study of Lerodalcibep and matching placebo in Hypercholesterolemia, Dyslipidemias and Primary Hypercholesterolemia, sponsored by Hasten Biopharmaceutical Co., Ltd.. Recruiting at 18 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Hasten Biopharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Planned enrollment
25th of 53
210 · median 207
Started
2024
with 5 others
Phase 3
25 of 59
4 open now
Primary completion
2026-02
later than 5 of 16 live
Registered
49th of 59
by date
Lead sponsor
2 of 59
Hasten Biopharmaceutical Co., Ltd.

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 25th largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2024, is one of 25 in phase 3, reaches primary completion later than 5 of the 16 other live ones, and was the 49th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W [≤31 days]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high/high risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.

Read the detailed description

This is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study. Participants who fulfill the inclusion and exclusion criteria will be enrolled at up to 35 study sites in mainland China.

All eligible participants will be randomized in a 2:1 ratio to HST101 or placebo dosed subcutaneously (Q4W [≤31 days]) in the initial 12-week randomized double-blind treatment period. After 12-week treatment, all the participants will enter to the 36-week open-label treatment period where those who are on HST101 will continue to receive HST101 in the same dosing regimen as dosed in the randomized period, and those who are on placebo will be switched to HST101 300 mg (Q4W [≤31 days]) administered subcutaneously.

The total study duration will be up to 55 weeks which includes a up to 3-week Screening Period, 12-week randomized, double-blind, placebo-controlled treatment period, 36-week open-label treatment period, followed by a 4-week follow-up period.

03

Conditions studied

  • Hypercholesterolemia
  • Dyslipidemias
  • Primary Hypercholesterolemia
  • Heterozygous Familial Hypercholesterolemia
  • Hyperlipidemia; Mixed
  • Metabolic Disease
  • ASCVD

Keywords

  • PCSK9 inhibitor
  • Lerodalcibep
  • LDL-C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written and signed form prior to any study-specific procedure;
  • Male or female participants ≥18 years of age at the screening visit;
  • Body weight ≥ 40 kg and (BMI) ≥18 and ≤35 kg/m2;
  • On a stable diet and lipid-lowering oral drugs (such as statins, ezetimibe or Hybutimibe, omega-3 compounds, fenofibrate, nicotinic acid, etc.) for at least 4 weeks prior to the first drug administration
  • LDL-C≥1.8 mmol/L (70 mg/dL) and TG≤4.52 mmol/L (400 mg/dL) at screening for ASCVD patients or those at very (ultra)-high risk for ASCVD, including patients with HeFH; LDL-C ≥ 2.6 mmol/L (100 mg/dL) and TG ≤ 4.52 mmol/L (400 mg/dL) at screening for patients at high-risk for ASCVD including patients with HeFH;
  • Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a of ≥6 weeks after the last dose; for those on 300 mg or 420 mg Q4W, the washout period is ≥10 weeks following last dose;
  • Female of must have a negative pregnancy test at the last screening visit and consent to use highly effective during the trial and 3 months after the last dose of drug.

Exclusion criteria

Exclusion Criteria:

  • Documented history of homozygous familial hypercholesterolemia (HoFH);
  • Estimated (eGFR)\<30 mL/min/1.73m2;
  • Active liver disease or hepatic dysfunction, history of liver transplant, and/or or AST >2.5 × at screening;
  • Poorly controlled thyroid disorder including hypothyroidism or hyperthyroidism;
  • Poorly controlled Type 1 or Type 2 diabetes mellitus defined as fasting blood glucose ≥11.0 mmol/L (200 mg/dL) and glycosylated () ≥ 9%;
  • Serious arrhythmia, MI, unstable angina pectoris, PCI, CABG, implantable cardioverter defibrillator, aortic valve surgery or stroke within 3 months prior to the first dose;
  • Planned cardiac surgery or revascularization during the study period;
  • (NYHA) Class III-IV heart failure;
  • Pregnant or lactating women;
  • Poorly controlled hypertension (SBP≥160 mmHg or DBP≥100 mmHg in a sitting position)
  • Unexplained creatine kinase (CK) > 5 x ULN (retested once is needed if suspected to be related to excessive exercise or abnormal activity);
  • LDL apheresis or plasma exchange within 2 months prior to the first dose;
  • , Treponema pallidum, or antibody test positive, or >ULN at screening;
  • History of prescription drug abuse, illicit drug use or alcohol abuse within 6 months prior to screening;
  • History of any major drug allergy, including allergy to protein biologics;
  • Participate another clinical trial within 30 days or less than 5 half-lifes (drug) before screening, whichever is longer
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    HST101(Lerodalcibep)

    300 mg subcutaneously Q4W

    Drug: Lerodalcibep

  • Placebo comparator
    Placebo

    subcutaneously Q4W

    Drug: matching placebo

Interventions

  • PCSK9 inhibitor

    Also known as: HST101, LIB003

  • Drugmatching placebo

    placebo

06

What researchers measure

Primary outcomes

  1. LDL-C change compared to Placebo

    Percent change in LDL-C level from baseline (calculated by Friedewald formula) compared to Placebo

    Time frame: 12 weeks

  2. Mean LDL-C change at Weeks 10 and 12 compared to Placebo

    Percent change in mean LDL-C level from baseline (calculated by Friedewald formula) compared to placebo at Weeks 10 and 12

    Time frame: 12 weeks

Secondary outcomes

  1. LDL-C change over time

    Absolute and percent change in LDL-C level from baseline at Weeks 4, 8, 10, and 12

    Time frame: 12 weeks

  2. Free PCSK9 change

    Absolute and Percent change in serum free PCSK9 level from baseline at Weeks 4,8 and 12

    Time frame: 12 weeks

  3. Other Lipid parameters change

    Absolute and Percent change in TC, TG, HDL-C, non-HDL-C, VLDL-C, Apo B and Lp(a) from baseline at Weeks 4,8 and 12

    Time frame: 12 weeks

  4. Percentage of patients achieving LDL-C goals recommended by 2023 Chinese guideline

    To assess the effect of HST101 on the percentage of patients achieving LDL-C\<2.6 mmol/L (high-risk for ASCVD patients), LDL-C\<1.8 mmol/L and \>50% reduction from baseline (very-high risk for ASCVD patients), LDL-C\<1.4 mmol/L and \>50% reduction from baseline (ultra-high risk for ASCVD patients)

    Time frame: 12 weeks

  5. Incidence of treatment-emergent adverse events

    Evaluation of adverse events, clinical lab tests, 12-lead ECG, vital signs, injection site reactions (ISRs)

    Time frame: 52 weeks

Other outcomes

  1. Long time free PCSK9 change

    Absolute and percent change in serum free PCSK9 levels from baseline at Weeks 16,20,24,36,48 and 52

    Time frame: 52 weeks

  2. Long time LDL-C change

    Absolute and percent change in LDL-C level from baseline at Weeks 16,20,22,24,36,48,50 and 52

    Time frame: 52 weeks

  3. Percentage of patients achieving LDL-C goals recommended by 2023 Chinese guideline

    To assess the effect of HST101 on the percentage of patients achieving LDL-C\<2.6 mmol/L (high-risk for ASCVD patients), LDL-C\<1.8 mmol/L and \>50% reduction from baseline (very-high risk for ASCVD patients), LDL-C\<1.4 mmol/L and \>50% reduction from baseline (ultra-high risk for ASCVD patients) at Weeks 16, 20, 24, 36, 48 and 52

    Time frame: 52 weeks

07

Study locations

17 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Feb 2026, 15 months after the start.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 15 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 23, 2024
StartActual
Nov 16, 2024
Primary completionEst.
Feb 2026
CompletionEst.
May 2026
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06568471
Lead sponsor
Hasten Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Nov 16, 2024
Primary completion
Feb 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Feb 6, 2025

Study contacts

Yong Huo
Contact
huoyong@263.net.cn
+86 13901333060
Yong Huo
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lerodalcibep

Start the discussion